Alexza Pharmaceuticals (ALXA) 10-Q 6 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ALXA	'
Entity Registrant Name	'Alexza Pharmaceuticals Inc.	'
Entity Central Index Key	'0001344413	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	17,278,554

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$23,807	$17,715	[1]
Marketable securities	8,650	'
Restricted cash	'	5,051	[1]
Accounts receivable	25	'
Inventory	2,061	'
Prepaid expenses and other current assets	1,795	852	[1]
Total current assets	36,338	23,618	[1]
Property and equipment, net	15,507	16,531	[1]
Other assets	1,727	402	[1]
Total assets	53,572	40,551	[1]
Current liabilities:	'	'
Accounts payable	4,067	2,147	[1]
Accrued clinical trial expenses	1,024	96	[1]
Other accrued expenses	4,317	3,599	[1]
Current portion of contingent consideration liability	2,200	3,500	[1]
Financing obligations	1,524	6,461	[1]
Current portion of deferred revenue	2,915	2,915	[1]
Total current liabilities	16,047	18,718	[1]
Deferred rent	6,809	8,059	[1]
Noncurrent portion of contingent consideration liability	41,100	6,100	[1]
Noncurrent portion of deferred revenues	2,915	5,101	[1]
Long-term debt	6,649	'
Stockholders' equity:	'	'
Preferred stock	'	'	[1]
Common stock	2	2	[1]
Additional paid-in-capital	348,584	337,184	[1]
Accumulated other comprehensive income	2	'
Accumulated deficit	-368,536	-334,613	[1]
Total stockholders' (deficit) equity	-19,948	2,573	[1]
Total liabilities and stockholders' equity	$53,572	$40,551	[1]
[1]	The condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date.

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Loss and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Revenue	$2,166	$729	$46,530	$3,341
Operating expenses:	'	'	'	'
Cost of goods sold	3,951	'	6,912	'
Research and development	5,457	4,784	16,475	14,826
General and administrative	3,097	2,338	12,016	6,487
Total operating expenses	12,505	7,122	35,403	21,313
(Loss) income from operations	-10,339	-6,393	11,127	-17,972
(Loss) gain on change in fair value of contingent consideration liability	-1,613	-200	-44,013	1,000
Interest and other income (expense), net	1	5	18	413
Interest expense	-461	-333	-1,055	-1,146
Net loss	-12,412	-6,921	-33,923	-17,705
Basic and diluted net loss per share	($0.72)	($0.52)	($2.06)	($1.55)
Shares used to compute basic and diluted net loss per share	17,238	13,235	16,467	11,394
Change in unrealized (loss)/gain on marketable securities	-3	'	2	'
Comprehensive loss	($12,415)	($6,921)	($33,921)	($17,705)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities:	'		'
Net loss	($33,923)		($17,705)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'		'
Share-based compensation	2,499		2,476
Change in fair value of contingent liability	44,013		-1,000
Recognition of right to borrow asset	-2,800		'
Amortization of debt discount, deferred interest and right to borrow asset	766		350
Amortization of premium (discount) on available-for-sale securities	-6		1
Depreciation and amortization	2,511		3,467
Gain on disposal of property and equipment	-15		-409
Changes in operating assets and liabilities:	'		'
Receivables	-25		10,000
Inventory	-2,061		'
Prepaid expenses and other current assets	-943		-117
Accounts payable	1,920		-1,771
Accrued clinical and other expenses	1,549		-688
Deferred revenues	-2,186		-1,890
Other liabilities	-1,250		-3,700
Net cash provided by (used in) operating activities	10,049		-10,986
Cash flows from investing activities:	'		'
Purchases of available-for-sale securities	-10,642		'
Maturities of available-for-sale securities	2,000		2,000
Decrease in noncurrent restricted cash	'		200
Purchases of property and equipment	-1,488		-214
Proceeds from the disposal of property and equipment	16		425
Net cash (used in) provided by investing activities	-10,114		2,411
Cash flows from financing activities:	'		'
Proceeds from issuance of common stock and warrants and exercise of stock options and stock purchase rights	6,446		35,177
Payment of contingent payments to Symphony Allegro Holdings, LLC	-10,313		-5,000
Change in current restricted cash	5,051		-6,469
Proceeds from financing obligations	10,000		'
Payments of financing obligations	-5,027		-4,520
Net cash provided by financing activities	6,157		19,188
Net increase in cash and cash equivalents	6,092		10,613
Cash and cash equivalents at beginning of period	17,715	[1]	14,902
Cash and cash equivalents at end of period	$23,807		$25,515
[1]	The condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date.

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
The Company and Basis of Presentation	'
	1. The Company and Basis of Presentation
	Business
	Alexza Pharmaceuticals, Inc. (the “Company”), was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, the Company changed its name to Alexza Corporation and in December 2001 became Alexza Molecular Delivery Corporation. In July 2005, the Company changed its name to Alexza Pharmaceuticals, Inc.
	The Company is a pharmaceutical development company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. The Company’s first commercial product, ADASUVE®, or Staccato® loxapine, and its product candidates are all based on the Staccato system, a proprietary technology developed by the Company. The Company’s facilities and employees are currently located in the United States, and the Company operates in one business segment.
	In May 2013, the Company entered into a License and Supply Agreement (the “Teva Agreement”) with Teva Pharmaceuticals USA, Inc. (“Teva”) to provide Teva with an exclusive license to develop and commercialize ADASUVE in the U.S. (see Note 10). The Company has an existing Collaboration, License and Supply Agreement (the “Ferrer Agreement”) with Grupo Ferrer Internacional, S.A. (“Ferrer”) for the commercialization of ADASUVE in Europe, Latin American, Russia and the Commonwealth of Independent States countries (see Note 10).
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim consolidated financial information. The results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013 or for any other interim period or any other future year.
	The accompanying unaudited condensed consolidated financial statements and notes to condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 26, 2013.
	Basis of Consolidation
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated.
	Significant Risks and Uncertainties
	The Company has incurred significant losses from operations since its inception and expects losses to continue for the foreseeable future. As of September 30, 2013, the Company had cash, cash equivalents and marketable securities of $32.5 million and working capital of $20.3 million. The Company believes that, based on its cash, cash equivalents and marketable securities balance at September 30, 2013, estimated product revenues, royalties and milestone payments associated with the sale of ADASUVE, remaining proceeds available under the Convertible Promissory Note and Agreement to Lend with Teva (the “Teva Note”, see Note 8) and its current expected cash usage, it has sufficient capital resources to meet its anticipated cash needs into the third quarter of 2014. The Company plans to raise additional capital to fund its operations and working capital, to develop its product candidates and to continue the development of its commercial manufacturing capabilities. In addition to product revenues, royalties and milestone payments, the Company plans to finance its operations through the sale of equity securities, utilization of debt arrangements, such as the Teva Note (see Note 8), or additional distribution or licensing collaborations. Such funding may not be available or may be on terms that are not favorable to the Company. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Revenue Recognition
	Revenue is recognized when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Prior to the second quarter of 2013, the Company’s revenue consisted primarily of amounts earned from collaboration agreements and under research grants with the National Institutes of Health. Beginning in the second quarter of 2013, the Company also had revenue from product sales.
	For collaboration agreements, revenues for non-refundable upfront license fee payments where the Company continues to have performance obligations are recognized as performance occurs and obligations are completed. Revenues for non-refundable upfront license fee payments where the Company does not have significant future performance obligations are recognized when the agreement is signed and the payments are due. See Note 10 for a description of the Company’s collaboration agreements.
	For multiple element arrangements, such as collaboration agreements in which a collaborator may purchase several deliverables, each deliverable is accounted for as a separate unit of accounting if both of the following criteria are met: (i) the delivered item or items have value to the customer on a standalone basis and (ii) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. The Company evaluates how the consideration should be allocated among the units of accounting and allocates revenue to each non-contingent element based upon the relative selling price of each element. The Company determines the relative selling price for each deliverable using (i) vendor-specific objective evidence (“VSOE”) of selling price, if it exists; (ii) third-party evidence (“TPE”) of selling price, if it exists; or (iii) the Company’s best estimated selling price for that deliverable if neither VSOE nor TPE of selling price exists for that deliverable. Revenue allocated to each element is then recognized when the basic four revenue recognition criteria described above are met for each element.
	For milestone payments received in connection with its collaboration agreements, the Company has elected to adopt the milestone method of accounting under Financial Accounting Standards Board Accounting Standards Codification 605-28, Milestone Method. Under the milestone method, revenues for payments which meet the definition of a milestone will be recognized as the respective milestones are achieved.
	Product revenue is recognized as follows:
		•		Persuasive Evidence of an Arrangement. The Company currently sells product through license and supply agreements with its collaborators, Ferrer and Teva. Persuasive evidence of an arrangement is generally determined by the receipt of an approved purchase order from the collaborator in connection with the terms of the license and supply agreements.
		•		Delivery. Typically, ownership of the product passes to the collaborator upon shipment. The Company’s current license and supply agreements also provide its collaborators with an acceptance period during which they may reject any product which does not conform to agreed-upon specifications. Because ADASUVE is a new product, a new technology and the Company’s first product to be commercialized and because the Company does not have a history of producing product to collaborator specifications, the Company will not consider delivery to have occurred until after the collaborator acceptance period has ended or the collaborator has affirmatively accepted the product. Once the Company has demonstrated over the course of time an ability to produce the product reliably to collaborator specifications, the Company will consider delivery to have occurred upon shipment in the absence of any other relevant shipment or acceptance terms.
		•		Sales Price Fixed or Determinable. Sales prices for product shipments are determined by the license and supply agreements and documented in the purchase orders. After the collaborator acceptance period has ended or the collaborator has affirmatively accepted the product, the Company’s collaborators do not have any product return or replacement rights, including for expired products.
		•		Collectability. Payment for the product is contractually obligated under the license and supply agreements. The Company will monitor payment histories for its collaborators and specific issues as they arise to determine whether collection is probable for a specific transaction and defer revenue as necessary.
	Royalty revenue from the Company’s collaboration agreements will be recognized as the Company receives information from its collaborators regarding product sales.
	Significant management judgment is used in the determination of revenue to be recognized and the period in which it is recognized.
	Inventory
	Inventory is stated at standard cost, which approximates actual cost, determined on a first-in first-out basis, not in excess of market value. Inventory includes the direct costs incurred to manufacture products combined with allocated manufacturing overhead, which consists of indirect costs, including labor and facility overhead. The Company is in the early stages of commercialization and has incurred significantly higher than normal indirect costs in the production of its inventory due to start-up manufacturing costs and low production volumes. The carrying cost of inventory is reduced so as to not be in excess of the market value of the inventory as determined by the contractual transfer prices to Ferrer and Teva. The excess over the market value is expensed to cost of goods sold. All costs associated with the ADASUVE manufacturing process incurred prior to the beginning of commercial manufacturing were expensed as a component of research and development expense. If information becomes available that suggests that all or certain of the inventory may not be realizable, the Company may be required to expense a portion, or all, of the capitalized inventory into cost of goods sold. Inventory, which is stated at the lower of cost or estimated market value, consists of the following at September 30, 2013 (in thousands):
	Raw materials		$	1,476
	Work in process			407
	Finished goods			178
	Inventory		$	2,061

Equity_Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Equity Transactions	'
	3. Equity Transactions
	Reverse Stock Split
	On June 12, 2012, the Company effected a 1-for-10 reverse stock split of the Company’s outstanding common stock resulting in a reduction of the Company’s total common stock issued and outstanding from 119.6 million shares to 12.0 million shares. The reverse stock split affected all stockholders of the Company’s common stock uniformly, and did not materially affect any stockholder’s percentage of ownership interest. The par value of the Company’s common stock remained unchanged at $0.0001 per share and the number of authorized shares of common stock remained the same after the reverse stock split.
	As the par value per share of the Company’s common stock remained unchanged at $0.0001 per share, a total of $11,000 was reclassified from common stock to additional paid-in capital. In connection with this reverse stock split, the number of shares of common stock reserved for issuance under the Company’s equity incentive, stock option and employee stock purchase plans (see Note 4) as well as the shares of common stock underlying outstanding stock options, restricted stock units and warrants were also proportionately reduced while the exercise prices of such stock options and warrants were proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.
	Equity Line of Credit
	In July 2012, the Company entered into a committed equity line of credit with Azimuth Opportunity, L.P. (“Azimuth”) pursuant to which the Company was granted the ability to sell up to $20 million of its common stock over an approximately 24-month period pursuant to the terms of a Common Stock Purchase Agreement (the “Purchase Agreement”). In addition to the foregoing amounts, in consideration for the performance of Azimuth’s obligations under the Purchase Agreement, the Company issued to Azimuth 80,429 shares of its common stock on July 23, 2012. In August and September 2012, the Company utilized $13.6 million under the facility by issuing 3,489,860 shares of its common stock to Azimuth at an average price of $3.88 per share, which resulted in $13.4 million in net proceeds to the Company. In May 2013, the Company utilized the remaining $6.4 million available under the facility by issuing 1,437,481 shares of its common stock to Azimuth at an average price of $4.48 per share, which resulted in $6.3 million of net proceeds to the Company. Shares were issued to Azimuth at a discount of 5% to the volume-weighted average price of the Company’s common stock over a preceding period of trading days. Shares sold under this facility were sold pursuant to a shelf registration statement declared effective by the SEC on July 3, 2012.

Fair_Value_Accounting

Fair Value Accounting	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Accounting	'
	4. Fair Value Accounting
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value. The three levels are:
		•		Level 1 — Quoted prices in active markets for identical assets or liabilities.
		•		Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents, and marketable securities) by major security type and liability measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 (in thousands):
	September 30, 2013		Level 1			Level 2			Level 3			Total
	Assets
	Money market funds		$	19,869		$	—		$	—		$	19,869
	Corporate debt securities			—			11,304			—			11,304
	Total assets		$	19,869		$	11,304		$	—		$	31,173
	Liabilities
	Contingent consideration liability		$	—		$	—		$	43,300		$	43,300
	Total liabilities		$	—		$	—		$	43,300		$	43,300
	December 31, 2012		Level 1			Level 2			Level 3			Total
	Assets
	Money market funds		$	17,307		$	—		$	—		$	17,307
	Total assets		$	17,307		$	—		$	—		$	17,307
	Liabilities
	Contingent consideration liability		$	—		$	—		$	9,600		$	9,600
	Total liabilities		$	—		$	—		$	9,600		$	9,600
	Cash equivalents and marketable securities
	The following table outlines the amortized cost, fair value and unrealized gain/(loss) for the Company’s financial assets by major security type as of September 30, 2013 (in thousands):
	September 30, 2013		Amortized			Fair Value			Unrealized
			Cost						Gain/(Loss)
	Money market funds		$	19,869		$	19,869		$	—
	Corporate debt securities			11,302			11,304			2
	Total			31,171			31,173			2
	Less amounts classified as cash equivalents			(22,523	)		(22,523	)		—
	Total marketable securities		$	8,648		$	8,650		$	2
	The Company did not have any unrealized gains or losses at December 31, 2012. The Company had no sales of marketable securities during the three and nine months ended September 30, 2013 or 2012. As of September 30, 2013, all of the Company’s marketable securities had original maturity dates of less than one year.
	The Company’s available-for-sale debt securities are valued utilizing a multi-dimensional relational model. Inputs, listed in approximate order of priority for use when available, include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data.
	Contingent Consideration Liability
	In connection with the exercise of the Company’s option to purchase all of the outstanding equity of Symphony Allegro, Inc. (“Allegro”) in 2009, the Company is obligated to make contingent cash payments to the former Allegro stockholders related to certain payments received by the Company from future collaboration agreements pertaining to ADASUVE/AZ-104 (Staccato loxapine) or AZ-002 (Staccato alprazolam). In order to estimate the fair value of the liability associated with the contingent cash payments, the Company prepared several cash flow scenarios for ADASUVE, AZ-104 and AZ-002, which are subject to the contingent payment obligation. Each potential cash flow scenario consisted of assumptions of the range of estimated milestone and license payments potentially receivable from such collaborations and assumed royalties received from future product sales. Based on these estimates, the Company computed the estimated payments to be made to the former Allegro stockholders. Payments were assumed to terminate upon the expiration of the related patents.
	The projected cash flow assumptions for ADASUVE in the United States are based on the Teva Agreement (see Note 10) and on internally and externally developed product sales forecasts. The timing and extent of the projected cash flows for ADASUVE for the territories licensed to Ferrer are based on the Ferrer Agreement (see Note 10). The timing and extent of the projected cash flows for the remaining territories for ADASUVE and worldwide territories for AZ-002 and AZ-104 were based on internal estimates for potential milestones and multiple product royalty scenarios and are also consistent in structure to the most recently negotiated collaboration agreements.
	The Company then assigned a probability to each of the cash flow scenarios based on several factors, including: the product candidate’s stage of development, preclinical and clinical results, technological risk related to the successful development of the different drug candidates, estimated market size, market risk and potential collaboration interest to determine a risk adjusted weighted average cash flow based on all of these scenarios. These probability and risk adjusted weighted average cash flows were then discounted utilizing the Company’s estimated weighted average cost of capital (“WACC”). The Company’s WACC considered the Company’s cash position, competition, risk of substitute products, and risk associated with the financing of the development projects. During the nine months ended September 30, 2013, the Company reduced the discount rate from 18.0% to 16.5% to reflect the Company’s current estimated WACC. The change in discount rate increased the net loss for the nine months ended September 30, 2013 by approximately $3,600,000 or $0.22 per share.
	This fair value measurement is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 measurements are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s assumptions in measuring fair value.
	The Company records any changes in the fair value of the contingent consideration liability in earnings in the period of the change. Certain events including, but not limited to, the timing and terms of any collaboration agreement, clinical trial results, approval or non-approval of any future regulatory submissions and the commercial success of ADASUVE, AZ-104 or AZ-002 could have a material impact on the fair value of the contingent consideration liability, and as a result, the Company’s results of operations and financial position for the impacted period.
	During the nine months ended September 30, 2013, the Company modified the assumptions regarding the timing and amount of certain cash flows primarily to reflect the increased probability that the Company would license the U.S. commercialization rights to ADASUVE to a third party in the first quarter of 2013 and the impact of the actual licensing and the terms of the Teva Agreement in the second quarter of 2013. These changes in assumptions, the change in the WACC in the nine months ended September 30, 2013 described above, the change in the projected U.S. ADASUVE launch date to the first quarter of 2014 and the effects of the passage of three and nine months, respectively, on the present value computation resulted in an increase to the net loss of $1,613,000 and $44,013,000, or $0.09 and $2.67 per share, for the three and nine months ended September 30, 2013, respectively.
	During the three and nine months ended September 30, 2012, the Company modified the assumptions regarding the timing and extent of certain cash flows primarily to reflect the three month extension of the review by the U.S. Food and Drug Administration (“FDA”) of the Company’s ADASUVE New Drug Application (“NDA”) from February 4, 2012 to May 4, 2012 and the receipt of the Complete Response Letter for the ADASUVE NDA in May 2012. This change in assumptions and the effects of the passage of time on the present value computation resulted in an increase to the net loss of $200,000, or $0.02 per share, for the three months ended September 30, 2012 and a decrease to the net loss of $1,000,000 or $0.09 per share for the nine months ended September 30, 2012.
	The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability for the three and nine months ended September 30, 2013 and 2012 (in thousands):
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Beginning balance		$	42,000		$	10,300		$	9,600		$	16,500
	Payments made			(313	)		—			(10,313	)		(5,000	)
	Adjustments to fair value measurement			1,613			200			44,013			(1,000	)
	Ending balance		$	43,300		$	10,500		$	43,300		$	10,500
	Financing Obligations
	The Company has estimated the fair value of its financing obligations (see Note 8) using the net present value of the payments discounted at an interest rate that is consistent with its estimated current borrowing rate for similar long-term debt. The Company believes the estimates used to measure the fair value of the financing obligations constitute Level 3 inputs.
	At September 30, 2013 and December 31, 2012, the estimated fair value of the Company’s financing obligations was $6,127,000 and $6,254,000, respectively and had book values of $8,173,000 and $6,461,000, respectively. The Company’s payment commitments associated with these debt instruments are comprised of interest payments and principal payments. The fair value of the Company’s debt will fluctuate with movements of interest rates, increasing in periods of declining rates of interest, and declining in periods of increasing rates of interest.

ShareBased_Compensation_Plans

Share-Based Compensation Plans	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation Plans	'
	5. Share-Based Compensation Plans
	2005 Equity Incentive Plan
	In December 2005, the Company’s Board of Directors adopted the 2005 Equity Incentive Plan (the “2005 Plan”) and authorized for issuance thereunder 108,879 shares of common stock. The 2005 Plan is an amendment and restatement of the Company’s previous stock option plans. Stock options issued under the 2005 Plan generally vest over four years, vesting is generally based on service time, and have a maximum contractual term of 10 years. Prior to vesting, restricted stock units do not have dividend equivalent rights, do not have voting rights and the shares underlying the restricted units are not considered issued and outstanding. Shares are issued on the date the restricted stock units vest.
	The 2005 Plan provides for annual reserve increases on the first day of each fiscal year commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases will be equal to the lesser of (i) 2% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, or (ii) 100,000 shares of common stock. The Company’s Board of Directors has the authority to designate a smaller number of shares by which the authorized number of shares of common stock will be increased prior to the last day of any calendar year. On each of January 1, 2013 and 2012 an additional 100,000 shares of the Company’s common stock were reserved for issuance under this provision. In May 2013, the Company’s stockholders approved an amendment to the 2005 Plan to increase the shares reserved by an additional 2,200,000 shares.
	2005 Non-Employee Directors’ Stock Option Plan
	In December 2005, the Company’s Board of Directors adopted the 2005 Non-Employee Directors’ Stock Option Plan (the “Directors’ Plan”) and authorized for issuance thereunder 25,000 shares of common stock. The Directors’ Plan provides for the automatic grant of non-statutory stock options to purchase shares of common stock to the Company’s non-employee directors, which vest over four years, and have a term of 10 years. The Directors’ Plan provides for an annual reserve increase to be added on the first day of each fiscal year, commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases will be equal to the number of shares subject to options granted during the preceding fiscal year less the number of shares that revert back to the share reserve during the preceding fiscal year. The Company’s Board of Directors has the authority to designate a smaller number of shares by which the authorized number of shares of common stock will be increased prior to the last day of any calendar year. On each of January 1, 2013 and 2012 an additional 19,812 and 20,000 shares, respectively, of the Company’s common stock were reserved for issuance under this provision. In May 2013, the Company’s stockholders approved an amendment to the Directors’ Plan to increase the shares reserved by an additional 200,000 shares.
	The following table sets forth the summary of option activity under the Company’s share-based compensation plans for the nine months ended September 30, 2013:
		Outstanding Options
		Number of			Weighted
		Shares			Average
					Exercise Price
	Outstanding at January 1, 2013		1,038,245		$	12.24
	Options granted		1,308,430			4.46
	Options exercised		(8,525	)		3.48
	Options canceled		(264,425	)		10.52
	Outstanding at September 30, 2013		2,073,725			7.59
	The intrinsic value of options exercised during the nine months ended September 30, 2013 was $11,000.
	The following table sets forth the summary of restricted stock unit activity under the Company’s share-based compensation plans for the nine months ended September 30, 2013:
		Number			Weighted
		Of			Average
		Shares			Grant-Date
					Fair Value
	Outstanding at January 1, 2013		—		$	—
	Granted		590,495			4.67
	Released		(17,795	)		4.2
	Forfeited		(45,750	)		4.68
	Outstanding at September 30, 2013		526,950			4.68
	As of September 30, 2013, 994,067 and 166,249 shares remained available for issuance under the 2005 Plan and the Directors’ Plan, respectively.
	2005 Employee Stock Purchase Plan
	In December 2005, the Company’s Board of Directors adopted the 2005 Employee Stock Purchase Plan (“ESPP”). The ESPP allows eligible employee participants to purchase shares of the Company’s common stock at a discount through payroll deductions. The ESPP consists of fixed offering periods of six months. Purchases are generally made on the last trading day of each October and April. Employees purchase shares at each purchase date at 85% of the market value of the Company’s common stock on their enrollment date or the end of the offering period, whichever price is lower.
	The ESPP provides for annual reserve increases on the first day of each fiscal year commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases are equal to the least of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, (ii) 75,000 shares of common stock, or (iii) a lesser amount determined by the Company’s Board of Directors.
	Pursuant to the ESPP, an additional 75,000 and 72,136 shares were reserved for issuance on January 1, 2013 and 2012, respectively. The Company issued 18,843 shares at a weighted average price of $3.65 under the ESPP during the nine months ended September 30, 2013 and 2,978 shares at a weighted average price of $5.30 under the ESPP during the nine months ended September 30, 2012. The Company did not issue shares under the ESPP during the three months ended September 30, 2013 or 2012. At September 30, 2013, 110,283 shares were available for issuance under the ESPP.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation	'
	6. Share-Based Compensation
	Employee Share-Based Awards
	Compensation cost for employee share-based awards is based on the grant-date fair value and is recognized over the vesting period of the applicable award on a straight-line basis. The Company issues employee share-based awards in the form of stock options and restricted stock units under the Company’s equity incentive plans, and stock purchase rights under the ESPP.
	Valuation of Stock Options, Restricted Stock Units and Stock Purchase Rights
	During the three and nine months ended September 30, 2013 and 2012, the per share weighted average fair value of employee stock options, restricted stock units and stock purchase rights granted were as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock Options	$	3.43		$	2.57		$	3.46		$	2.58
	Restricted Stock Units		—			—			4.67			4.9
	Stock Purchase Rights		1.41			3.31			1.53			4.23
	The estimated grant date fair values of the stock options and stock purchase rights were calculated using the Black-Scholes valuation model with the following weighted average assumptions:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock Option Plans
	Expected term		5.0 years			5.0 years			5.0 years			5.0 years
	Expected volatility		98	%		98	%		100	%		98	%
	Risk-free interest rate		1.47	%		0.62	%		0.83	%		0.63	%
	Dividend yield		0	%		0	%		0	%		0	%
	Employee Stock Purchase Plan
	Expected term		0.5 years			0.5 years			0.5 years			0.6 years
	Expected volatility		63	%		135	%		70	%		96	%
	Risk-free interest rate		0.12	%		0.15	%		0.13	%		0.13	%
	Dividend yield		0	%		0	%		0	%		0	%
	The estimated fair value of restricted stock units awards is calculated based on the market price of the Company’s common stock on the date of grant, reduced by the present value of dividends expected to be paid on the Company’s common stock prior to vesting of the restricted stock unit. The Company’s estimate assumes no dividends will be paid prior to the vesting of the restricted stock unit.
	As of September 30, 2013, there was $4,470,000, $1,974,000 and $12,000 of total unrecognized compensation expense related to unvested stock option awards, restricted stock units and stock purchase rights, respectively, which are expected to be recognized over a weighted average period of 2.1 years, 3.5 years, and 0.1 years, respectively.

Net_Loss_per_Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	7. Net Loss per Share
	Basic and diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. The following items were excluded in the net loss per share calculation for the three and nine months ended September 30, 2013 and 2012 because the inclusion of such items would have had an anti-dilutive effect:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Stock options		2,031,155		834,463		1,541,034		790,892
	Restricted stock units		526,950		150,274		263,475		150,609
	Warrants to purchase common stock		6,462,066		6,462,066		6,462,066		5,362,082
	Convertible debt		1,115,250		—		557,625		—

Financing_Obligations

Financing Obligations	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Financing Obligations	'
	8. Financing Obligations
	Hercules Technology Growth Capital
	In May 2010, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with Hercules Technology Growth Capital, Inc. (“Hercules”). Under the terms of the Loan Agreement, the Company borrowed $15,000,000 at an interest rate of the higher of (i) 10.75% or (ii) 6.5% plus the prime rate as reported in the Wall Street Journal, with a maximum interest rate of 14% and issued to Hercules a secured term promissory note evidencing the loan. The Company made interest-only payments through January 2011 and beginning in February 2011 the loan was repaid in 33 equal monthly installments. The loan was paid in full in October 2013.
	In conjunction with the loan, the Company issued to Hercules a five-year warrant to purchase 37,639 shares of the Company’s common stock at a price of $26.90 per share. The warrant was immediately exercisable and expires in May 2015. The Company estimated the fair value of this warrant as of the issuance date to be $921,000 which was recorded as a debt discount to the loan and consequently a reduction to the carrying value of the loan. The fair value of the warrant was calculated using the Black-Scholes option valuation model, and was based on the contractual term of the warrant of five years, a risk-free interest rate of 2.31%, expected volatility of 84% and a 0% expected dividend yield. The Company also recorded fees paid to Hercules as a debt discount, which further reduced the carrying value of the loan. The debt discount is being amortized to interest expense.
	In January 2012, the Company and Hercules amended the Loan Agreement to require the Company to maintain an amount equal to the outstanding principal balance of the loan in a restricted account. On January 3, 2013, Hercules removed the requirement to maintain the restricted account and the funds were no longer classified as restricted cash.
	Autoliv ASP, Inc.
	In June 2010, in return for transfer to the Company of all right, title and interest in a production line for the commercial manufacture of chemical heat packages completed or to be completed by Autoliv ASP, Inc. (“Autoliv”) on behalf of the Company, the Company paid Autoliv $4 million in cash and issued Autoliv a $4 million unsecured promissory note. In February 2011, the Company entered into an agreement to amend the terms of the unsecured promissory note. Under the terms of that amendment, the original $4 million note was cancelled and a new unsecured promissory note was issued with a reduced principal amount of $2.8 million (the “New Note”).
	The New Note bears interest beginning on January 1, 2011 at 8% per annum and is being paid in 48 consecutive and equal monthly installments of approximately $68,000.
	In October 2013, Autoliv notified the Company of their intent to terminate, effective October 2016, the Manufacturing and Supply Agreement (the “Manufacture Agreement”). Prior to October 2016, Autoliv and the Company remain fully obligated to perform pursuant to the terms of both the Manufacture Agreement and the New Note.
	Teva Pharmaceuticals USA, Inc.
	In May 2013, concurrent with the Teva Agreement, the Company entered into the Teva Note. Under the terms of the Teva Note, the Company may, upon written notice to Teva, draw upon the Teva Note to fund agreed operating budgets related to ADASUVE. The aggregate drawdowns may total up to $25 million and will be due and payable on the fifth anniversary of the signing of the Teva Note. The Company may prepay, from time to time, up to one-half of the total amounts advanced plus the related interest outstanding at any time prior to the maturity date. At the maturity date, Teva will have the right to convert the then outstanding amounts into shares of the Company’s common stock at a conversion price of $4.4833 per share. The Teva Note bears simple interest of 4% per year. The Company has two years from the effective date of the Teva Note to receive advances.
	In the three months ended September 30, 2013, the Company drew down $10,000,000 against the Teva Note. Because the contractual conversion price was less than the market value of the Company’s common stock at the time of the drawdown, the Company calculated the value of the beneficial conversion feature of the convertible note and recorded an increase to additional paid-in-capital and a discount on the Teva Note of $2,455,000 which will be amortized to interest expense over the life of the borrowing. Additionally, the Company reclassified the relative portion of the unamortized right-to-borrow (see Note 10) against the Teva Note in the amount of $901,000 which will also be amortized to interest expense over the life of the borrowing. The effective interest rate of the Teva Note, which takes into consideration the beneficial conversion feature and the right-to-borrow discounts, is 13.9%.
	Future scheduled principal payments under the debt obligations as of September 30, 2013 are as follows (in thousands):
		Total
	2013 - remaining 3 months	$	747
	2014		781
	2015		—
	2016		—
	Thereafter		10,000
	Total	$	11,528

Facility_Leases

Facility Leases	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]	'
Facility Leases	'
	9. Facility Leases
	The Company leased two buildings, at 2023 Stierlin Court and 2091 Stierlin Court, in Mountain View, California, referred to herein as the “2023 Building” and the “2091 Building”, respectively, which the Company began to occupy in the fourth quarter of 2007. The Company recognizes rental expense on the facilities on a straight line basis over the initial term of the lease. Differences between the straight line rent expense and rent payments are classified as deferred rent liability on the balance sheet. The lease for the 2091 Building expires on March 31, 2018, and the Company has two options to extend the lease for five years each.
	Effective March 30, 2012, the Company terminated the lease for the 2023 Building, totaling 41,290 square feet, and concurrently cancelled the two subleases associated with the 2023 Building. At the time of the termination, the Company recorded a non-cash contra-expense of $1,421,000 in general and administrative expenses, which is the net effect of reversing the deferred rent liability associated with the 2023 Building lease and subleases and the accelerated depreciation of fixed assets associated with the 2023 Building.

License_Agreements

License Agreements	9 Months Ended
	Sep. 30, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
License Agreements	'
	10. License Agreements
	Cypress Bioscience, Inc.
	In August 2010, the Company entered into a license and development agreement with Cypress Bioscience, Inc. (“Cypress”) for Staccato nicotine (the “Cypress Agreement”). According to the terms of the Cypress Agreement, Cypress paid the Company a non-refundable upfront payment of $5 million to acquire the worldwide license for the Staccato nicotine technology. In January 2011, Cypress was acquired by Ramius Value and Opportunity Advisors LLC; Royalty Pharma, U.S. Partner, LP; Royalty Pharma U.S. Partners 2008, LP; and RP Investment Corporation (collectively, “Royalty Pharma”), at which time Royalty Pharma became Cypress’ successor in interest to the Cypress Agreement.
	Following the completion of certain preclinical and clinical milestones relating to the Staccato nicotine technology, if Royalty Pharma elects to continue the development of Staccato nicotine, Royalty Pharma will be obligated to pay the Company an additional technology transfer payment of $1 million. The Company has a carried interest of 50% prior to the technology transfer payment, and 10% after the completion of certain development activities and receipt of the technology transfer payment, subject to adjustment in certain circumstances, in the net proceeds of any sale or license by Royalty Pharma of the Staccato nicotine assets and the carried interest will be subject to put and call rights in certain circumstances.
	Royalty Pharma has the responsibility for preclinical, clinical and regulatory aspects of the development of Staccato nicotine, along with the commercialization of the product. Royalty Pharma paid the Company a total of $3.9 million in research and development funding for the Company’s efforts to execute a development plan culminating with the delivery of clinical trial materials for a Phase 1 study with Staccato nicotine.
	For revenue recognition purposes, the Company viewed the Cypress Agreement as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis and whether objective and reliable evidence of fair value of the undelivered items exist. Deliverables that do not meet these criteria are not evaluated separately for the purpose of revenue recognition. For a single unit of accounting, payments received are recognized in a manner consistent with the final deliverable. The Company was unable to allocate a fair value to each of the deliverables outlined in the Cypress Agreement and therefore accounted for the deliverables as a single unit of accounting. The Company has not recognized revenues under the Cypress Agreement in 2013 and recognized $0 and $1,259,000 of revenue under the Cypress Agreement in the three and nine months ended September 30, 2012, respectively. At September 30, 2013, the Company had no deferred revenues related to the Cypress Agreement.
	In January 2013, the Company and Royalty Pharma amended the Cypress Agreement. Under the amended terms, Royalty Pharma will use commercially reasonable efforts to sell or license the Staccato nicotine technology and the Company will use commercially reasonable efforts to support Royalty Pharma’s efforts. If Royalty Pharma does not sell or license the Staccato nicotine technology by December 31, 2013, the Cypress Agreement will automatically terminate, at which time all rights to the Staccato nicotine technology will revert back to the Company.
	Grupo Ferrer Internacional, S.A.
	On October 5, 2011, the Company and Ferrer entered into the Ferrer Agreement to commercialize ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries (the “Ferrer Territories”). Under the terms of the Ferrer Agreement, the Company received an upfront cash payment of $10 million, of which $5 million was paid to the former Allegro stockholders (see above in Note 4). The Ferrer Agreement provided for up to an additional $51 million in additional milestone payments, contingent on Marketing Authorization Application (“MAA”) approval, individual country commercial sales initiation and royalty payments based on cumulative net sales targets in the Ferrer Territories. The Company was responsible for filing and obtaining approval of the ADASUVE MAA submitted to the European Medicines Agency (“EMA”) for an opinion regarding the potential approval of ADASUVE and subsequent decision by the European Commission (“EC”). The Company is also responsible for all post-approval clinical studies required to be performed by the EMA and EC. Ferrer will be responsible for satisfaction of all other regulatory and pricing requirements to market and sell ADASUVE in the Ferrer Territories. Ferrer will have the exclusive rights to commercialize the product in the Ferrer Territories. The Company will supply ADASUVE to Ferrer for all of its commercial sales, and will receive a specified per-unit transfer price paid in Euros. Either party may terminate the Ferrer Agreement for the other party’s uncured material breach or bankruptcy. The Ferrer Agreement continues in effect on a country-by-country basis until the later of the last to expire patent covering ADASUVE in such country or 12 years after first commercial sale. The Ferrer Agreement is subject to earlier termination in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party.
	In March 2012, the Company entered into an amendment to the Ferrer Agreement. Ferrer and the Company agreed to eliminate the potential MAA approval milestone payment in exchange for Ferrer’s purchase of 241,936 shares ($3 million) of the Company’s common stock for $12.40 per share, which reflected a premium on the fair value of the Company’s common stock of approximately $1,452,000.
	The Company evaluated whether the delivered elements under the Ferrer Agreement have value on a stand-alone basis and allocated revenue to the identified units of accounting based on relative fair value. The Company determined that the license and the development and regulatory services are a single unit of accounting as the licenses were determined to not have stand-alone value. The Company has begun to deliver all elements of the arrangement and is recognizing the $10 million upfront payment as revenue ratably over the estimated performance period of the agreement of four years. The $1,452,000 premium received from the sale of common stock to Ferrer is additional consideration received pursuant to the Ferrer Agreement and does not pertain to a separate deliverable or element of the arrangement, and thus is being deferred and recognized as revenue in a manner consistent with the $10 million upfront payment.
	The Ferrer Agreement provides for the Company to receive up to $48 million of additional payments related to first commercial sales in nine (9) identified countries and to cumulative net sales targets in the Ferrer Territories. The cumulative net sales targets will be recognized as royalty revenue when each target is earned and payable to the Company. The first commercial sales payments will be recognized utilizing the milestone method of revenue recognition. The Company believes each of these milestones is substantive as there is uncertainty that the milestones will be met, the milestone can only be achieved as a result of the Company’s past performance and the achievement of the milestone will result in additional payment to the Company. The Company will recognize milestone revenue upon first commercial sales in each of these identified countries. In the third quarter of 2013, the Company received and recognized revenue on the first milestone in the amount of $1,250,000, of which $312,500 was paid to the former stockholders of Allegro.
	During the three and nine months ended September 30, 2013, the Company recognized $729,000 and $2,187,000, respectively, of license revenue related to the Ferrer Agreement, and license revenue of $729,000 and $2,082,000, respectively, in the same periods of 2012. At September 30, 2013 the Company had deferred revenue of $5,829,000 related to the Ferrer Agreement.
	Teva Pharmaceuticals USA, Inc.
	In May 2013, the Company entered into the Teva Agreement to provide Teva with an exclusive license to develop and commercialize ADASUVE in the U.S. Under the terms of the Teva Agreement, Teva will be responsible for all U.S. development, regulatory and commercialization activities for ADASUVE, including the U.S. post-approval clinical studies and any additional clinical trials for new indications. Teva has the full right to sublicense its rights and obligations under the Teva Agreement. The Company is responsible for manufacturing and supplying ADASUVE to Teva for clinical trials and commercial sales. Teva has the exclusive rights to commercialize ADASUVE in the U.S. and the co-exclusive rights (with the Company and its affiliates) to manufacture the product.
	The Company received an upfront cash payment of $40 million from Teva, $10 million of which was paid to the former stockholders of Allegro. The Company is eligible to receive up to $195 million in additional payments contingent on Teva’s successful completion of the ADASUVE post-approval studies in the U.S. and Teva achieving specified net sales targets. In addition to these payments, the Company will supply ADASUVE to Teva for all of its clinical trials and commercial sales, and the Company will receive a specified per-unit transfer price in an amount of the greater of the Company’s costs of commercial production or a specified per-unit price. Teva will make tiered royalty payments based on net commercial sales of ADASUVE in the U.S.
	Unless earlier terminated, the Teva Agreement continues in effect until the later of the last to expire patent covering ADASUVE in the U.S. or a specified number of years after first commercial sale. The Agreement is subject to earlier termination in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party. Teva may also terminate the Teva Agreement in the event the FDA requires withdrawal or suspension of ADASUVE from the market due to safety reasons or, subject to a specified period of notice, for Teva’s convenience at any time following the first anniversary of the Teva Agreement.
	The Company evaluated whether the delivered elements under the Teva Agreement have value on a stand-alone basis and allocated revenue to the identified units of accounting based on relative fair value. The Company determined that the license fees are a single unit of accounting and valued the license based on its best estimate of selling price, as VSOE and TPE of the selling price could not be determined. The selling price was estimated using discounted projected cash flows related to the licensed territory. The Company has delivered the license to Teva and recognized the $40 million non-refundable upfront payment as revenue.
	As described in Note 8, in connection with the Teva Agreement, the Company received a right-to-borrow under the Teva Note. The Company has the ability to draw on the Teva Note in amounts not to exceed $25 million, over a two year period. As outlined in Note 8, the Teva Note has a fixed conversion price and interest rate. This right-to-borrow was considered additional consideration provided by Teva to the Company pursuant to the Teva Agreement. The Company performed an analysis using a Monte Carlo simulation model with a volatility rate of 70% and an estimated debt yield of 15%. Based on this analysis, the Company determined that the fair value of this right-to-borrow was $2.8 million. The Company recorded this amount as revenue and as an other asset upon entering into the Teva Note. The asset is being amortized to interest expense over the two year period during which the Company is able to exercise the right-to-borrow. As the Company draws on the Teva Note, the relative portion of the unamortized right-to-borrow will be accounted for as a cost of borrowing and will be amortized to interest expense over the life of the borrowing. In the third quarter of 2013, the Company drew down $10,000,000 against the Teva Note and reclassified $901,000 of the unamortized right-to-borrow as a cost of borrowing to be amortized to interest expense over the life of the borrowing. The Company recorded $348,000 and $555,000 in interest expense related to the right-to-borrow in the three and nine months ended September 30, 2013, respectively.
	As noted above, the Company is eligible to receive up to $195 million of additional payments from Teva related to the successful completion of the ADASUVE post-approval studies in the U.S. and Teva achieving specified net sales targets. The payments related to net sales targets will be recognized as royalty revenue when each target is earned and payable to the Company. The payment related to the completion of the ADASUVE post-approval studies will be recognized upon completion of the studies when the payment is earned and payable to the Company.

Autoliv_Manufacturing_and_Supp

Autoliv Manufacturing and Supply Agreement	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Autoliv Manufacturing and Supply Agreement	'
	11. Autoliv Manufacturing and Supply Agreement
	In November 2007, the Company entered into a Manufacturing and Supply Agreement (the “Manufacture Agreement”) with Autoliv relating to the commercial supply of chemical heat packages that can be incorporated into the Company’s Staccato device (the “Chemical Heat Packages”). Autoliv had developed these Chemical Heat Packages for the Company pursuant to a development agreement between Autoliv and the Company. Under the terms of the Manufacture Agreement, Autoliv agreed to develop a manufacturing line capable of producing 10 million Chemical Heat Packages a year.
	In June 2010 and February 2011, the Company entered into agreements to amend the terms of the Manufacture Agreement (together the “Amendments”). Under the terms of the first Amendment, the Company paid Autoliv $4 million and issued Autoliv a $4 million unsecured promissory note in return for a production line for the commercial manufacture of Chemical Heat Packages. Each production line is comprised of two identical and self-sustaining “cells,” and the first such cell was completed, installed and qualified in connection with such Amendment. Under the terms of the second Amendment, the original $4 million note was cancelled and a new note was issued with a reduced principal amount of $2.8 million (the “New Note”), and production on the second cell ceased. The New Note is payable in 48 equal monthly installments of approximately $68,000. In the event that the Company requests completion of the second cell of the first production line for the commercial manufacture of Chemical Heat Packages, Autoliv will complete, install and fully qualify such second cell for a cost to the Company of $1.2 million and Autoliv will transfer ownership of such cell to the Company upon the payment in full of such $1.2 million and the New Note.
	The provisions of the Amendments supersede (a) the Company’s obligation set forth in the Manufacture Agreement to reimburse Autoliv for certain expenses related to the equipment and tooling used in production and testing of the Chemical Heat Packages in an amount of up to $12 million upon the earliest of December 31, 2011, 60 days after the termination of the Manufacture Agreement or 60 days after approval by the FDA of an NDA filed by the Company, and (b) the obligation of Autoliv to transfer possession of such equipment and tooling.
	Subject to certain exceptions, Autoliv has agreed to manufacture, assemble and test the Chemical Heat Packages solely for the Company in conformance with the Company’s specifications. The Company will pay Autoliv a specified purchase price, which varies based on annual quantities ordered by the Company, per Chemical Heat Package delivered. In October 2013, Autoliv notified the Company of their intent to terminate, effective October 2016, the Manufacture Agreement. Prior to October 2016, Autoliv and the Company remain fully obligated to perform pursuant to the terms of both the Manufacture Agreement and the New Note. The Manufacture Agreement provides that during the term of the Manufacture Agreement, Autoliv will be the Company’s exclusive supplier of the Chemical Heat Packages. In addition, the Manufacture Agreement grants Autoliv the right to negotiate for the right to supply commercially any second generation Chemical Heat Package (a “Second Generation Product”) and provides that the Company will pay Autoliv certain royalty payments if the Company manufactures Second Generation Products itself or if the Company obtains Second Generation Products from a third party manufacturer. Upon the termination of the Manufacture Agreement, the Company will be required, on an ongoing basis, to pay Autoliv certain royalty payments related to the manufacture of the Chemical Heat Packages by the Company or third party manufacturers.

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim consolidated financial information. The results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013 or for any other interim period or any other future year.
	The accompanying unaudited condensed consolidated financial statements and notes to condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 26, 2013.
Basis of Consolidation	'
	Basis of Consolidation
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated.
Significant Risks and Uncertainties	'
	Significant Risks and Uncertainties
	The Company has incurred significant losses from operations since its inception and expects losses to continue for the foreseeable future. As of September 30, 2013, the Company had cash, cash equivalents and marketable securities of $32.5 million and working capital of $20.3 million. The Company believes that, based on its cash, cash equivalents and marketable securities balance at September 30, 2013, estimated product revenues, royalties and milestone payments associated with the sale of ADASUVE, remaining proceeds available under the Convertible Promissory Note and Agreement to Lend with Teva (the “Teva Note”, see Note 8) and its current expected cash usage, it has sufficient capital resources to meet its anticipated cash needs into the third quarter of 2014. The Company plans to raise additional capital to fund its operations and working capital, to develop its product candidates and to continue the development of its commercial manufacturing capabilities. In addition to product revenues, royalties and milestone payments, the Company plans to finance its operations through the sale of equity securities, utilization of debt arrangements, such as the Teva Note (see Note 8), or additional distribution or licensing collaborations. Such funding may not be available or may be on terms that are not favorable to the Company. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.
Revenue Recognition	'
	Revenue Recognition
	Revenue is recognized when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Prior to the second quarter of 2013, the Company’s revenue consisted primarily of amounts earned from collaboration agreements and under research grants with the National Institutes of Health. Beginning in the second quarter of 2013, the Company also had revenue from product sales.
	For collaboration agreements, revenues for non-refundable upfront license fee payments where the Company continues to have performance obligations are recognized as performance occurs and obligations are completed. Revenues for non-refundable upfront license fee payments where the Company does not have significant future performance obligations are recognized when the agreement is signed and the payments are due. See Note 10 for a description of the Company’s collaboration agreements.
	For multiple element arrangements, such as collaboration agreements in which a collaborator may purchase several deliverables, each deliverable is accounted for as a separate unit of accounting if both of the following criteria are met: (i) the delivered item or items have value to the customer on a standalone basis and (ii) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. The Company evaluates how the consideration should be allocated among the units of accounting and allocates revenue to each non-contingent element based upon the relative selling price of each element. The Company determines the relative selling price for each deliverable using (i) vendor-specific objective evidence (“VSOE”) of selling price, if it exists; (ii) third-party evidence (“TPE”) of selling price, if it exists; or (iii) the Company’s best estimated selling price for that deliverable if neither VSOE nor TPE of selling price exists for that deliverable. Revenue allocated to each element is then recognized when the basic four revenue recognition criteria described above are met for each element.
	For milestone payments received in connection with its collaboration agreements, the Company has elected to adopt the milestone method of accounting under Financial Accounting Standards Board Accounting Standards Codification 605-28, Milestone Method. Under the milestone method, revenues for payments which meet the definition of a milestone will be recognized as the respective milestones are achieved.
	Product revenue is recognized as follows:
		•		Persuasive Evidence of an Arrangement. The Company currently sells product through license and supply agreements with its collaborators, Ferrer and Teva. Persuasive evidence of an arrangement is generally determined by the receipt of an approved purchase order from the collaborator in connection with the terms of the license and supply agreements.
		•		Delivery. Typically, ownership of the product passes to the collaborator upon shipment. The Company’s current license and supply agreements also provide its collaborators with an acceptance period during which they may reject any product which does not conform to agreed-upon specifications. Because ADASUVE is a new product, a new technology and the Company’s first product to be commercialized and because the Company does not have a history of producing product to collaborator specifications, the Company will not consider delivery to have occurred until after the collaborator acceptance period has ended or the collaborator has affirmatively accepted the product. Once the Company has demonstrated over the course of time an ability to produce the product reliably to collaborator specifications, the Company will consider delivery to have occurred upon shipment in the absence of any other relevant shipment or acceptance terms.
		•		Sales Price Fixed or Determinable. Sales prices for product shipments are determined by the license and supply agreements and documented in the purchase orders. After the collaborator acceptance period has ended or the collaborator has affirmatively accepted the product, the Company’s collaborators do not have any product return or replacement rights, including for expired products.
		•		Collectability. Payment for the product is contractually obligated under the license and supply agreements. The Company will monitor payment histories for its collaborators and specific issues as they arise to determine whether collection is probable for a specific transaction and defer revenue as necessary.
	Royalty revenue from the Company’s collaboration agreements will be recognized as the Company receives information from its collaborators regarding product sales.
	Significant management judgment is used in the determination of revenue to be recognized and the period in which it is recognized.
Inventory	'
	Inventory
	Inventory is stated at standard cost, which approximates actual cost, determined on a first-in first-out basis, not in excess of market value. Inventory includes the direct costs incurred to manufacture products combined with allocated manufacturing overhead, which consists of indirect costs, including labor and facility overhead. The Company is in the early stages of commercialization and has incurred significantly higher than normal indirect costs in the production of its inventory due to start-up manufacturing costs and low production volumes. The carrying cost of inventory is reduced so as to not be in excess of the market value of the inventory as determined by the contractual transfer prices to Ferrer and Teva. The excess over the market value is expensed to cost of goods sold. All costs associated with the ADASUVE manufacturing process incurred prior to the beginning of commercial manufacturing were expensed as a component of research and development expense. If information becomes available that suggests that all or certain of the inventory may not be realizable, the Company may be required to expense a portion, or all, of the capitalized inventory into cost of goods sold. Inventory, which is stated at the lower of cost or estimated market value, consists of the following at September 30, 2013 (in thousands):
	Raw materials		$	1,476
	Work in process			407
	Finished goods			178
	Inventory		$	2,061

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Inventory	'
	Inventory, which is stated at the lower of cost or estimated market value, consists of the following at September 30, 2013 (in thousands):
	Raw materials	$	1,476
	Work in process		407
	Finished goods		178
	Inventory	$	2,061

Fair_Value_Accounting_Tables

Fair Value Accounting (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Financial Assets by Major Security Type and Liability Measured at Fair Value on Recurring Basis	'
	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents, and marketable securities) by major security type and liability measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 (in thousands):
	September 30, 2013	Level 1			Level 2			Level 3			Total
	Assets
	Money market funds	$	19,869		$	—		$	—		$	19,869
	Corporate debt securities		—			11,304			—			11,304
	Total assets	$	19,869		$	11,304		$	—		$	31,173
	Liabilities
	Contingent consideration liability	$	—		$	—		$	43,300		$	43,300
	Total liabilities	$	—		$	—		$	43,300		$	43,300
	December 31, 2012	Level 1			Level 2			Level 3			Total
	Assets
	Money market funds	$	17,307		$	—		$	—		$	17,307
	Total assets	$	17,307		$	—		$	—		$	17,307
	Liabilities
	Contingent consideration liability	$	—		$	—		$	9,600		$	9,600
	Total liabilities	$	—		$	—		$	9,600		$	9,600
Schedule of Cash Equivalents and Marketable Securities	'
	The following table outlines the amortized cost, fair value and unrealized gain/(loss) for the Company’s financial assets by major security type as of September 30, 2013 (in thousands):
	September 30, 2013	Amortized			Fair			Unrealized
		Cost			Value			Gain/(Loss)
	Money market funds	$	19,869		$	19,869		$	—
	Corporate debt securities		11,302			11,304			2
	Total		31,171			31,173			2
	Less amounts classified as cash equivalents		(22,523	)		(22,523	)		—
	Total marketable securities	$	8,648		$	8,650		$	2
Fair Value Measurement of Contingent Consideration Liability	'
	The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability for the three and nine months ended September 30, 2013 and 2012 (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Beginning balance	$	42,000		$	10,300		$	9,600		$	16,500
	Payments made		(313	)		—			(10,313	)		(5,000	)
	Adjustments to fair value measurement		1,613			200			44,013			(1,000	)
	Ending balance	$	43,300		$	10,500		$	43,300		$	10,500

ShareBased_Compensation_Plans_

Share-Based Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Option Activity under Company's Share-Based Compensation Plans	'
	The following table sets forth the summary of option activity under the Company’s share-based compensation plans for the nine months ended September 30, 2013:
		Outstanding Options
		Number of			Weighted
		Shares			Average
					Exercise Price
	Outstanding at January 1, 2013		1,038,245		$	12.24
	Options granted		1,308,430			4.46
	Options exercised		(8,525	)		3.48
	Options canceled		(264,425	)		10.52
	Outstanding at September 30, 2013		2,073,725			7.59
Summary of Restricted Stock Unit Activity under Company's Share-Based Compensation Plans	'
	The following table sets forth the summary of restricted stock unit activity under the Company’s share-based compensation plans for the nine months ended September 30, 2013:
		Number			Weighted
		Of			Average
		Shares			Grant-Date
					Fair Value
	Outstanding at January 1, 2013		—		$	—
	Granted		590,495			4.67
	Released		(17,795	)		4.2
	Forfeited		(45,750	)		4.68
	Outstanding at September 30, 2013		526,950			4.68

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Weighted Average Fair Value of Employee Stock Options, Restricted Stock Units and Stock Purchase Rights Granted	'
	During the three and nine months ended September 30, 2013 and 2012, the per share weighted average fair value of employee stock options, restricted stock units and stock purchase rights granted were as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock Options	$	3.43		$	2.57		$	3.46		$	2.58
	Restricted Stock Units		—			—			4.67			4.9
	Stock Purchase Rights		1.41			3.31			1.53			4.23
Estimated Grant Date Fair Values of Stock Options with Weighted Average Assumptions	'
	The estimated grant date fair values of the stock options and stock purchase rights were calculated using the Black-Scholes valuation model with the following weighted average assumptions:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock Option Plans
	Expected term		5.0 years			5.0 years			5.0 years			5.0 years
	Expected volatility		98	%		98	%		100	%		98	%
	Risk-free interest rate		1.47	%		0.62	%		0.83	%		0.63	%
	Dividend yield		0	%		0	%		0	%		0	%
	Employee Stock Purchase Plan
	Expected term		0.5 years			0.5 years			0.5 years			0.6 years
	Expected volatility		63	%		135	%		70	%		96	%
	Risk-free interest rate		0.12	%		0.15	%		0.13	%		0.13	%
	Dividend yield		0	%		0	%		0	%		0	%

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Anti-Dilutive Securities Excluded from Net Loss per Share	'
	The following items were excluded in the net loss per share calculation for the three and nine months ended September 30, 2013 and 2012 because the inclusion of such items would have had an anti-dilutive effect:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Stock options		2,031,155		834,463		1,541,034		790,892
	Restricted stock units		526,950		150,274		263,475		150,609
	Warrants to purchase common stock		6,462,066		6,462,066		6,462,066		5,362,082
	Convertible debt		1,115,250		—		557,625		—

Financing_Obligations_Tables

Financing Obligations (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Future Scheduled Principal Payments under Term Loan Agreements	'
	Future scheduled principal payments under the debt obligations as of September 30, 2013 are as follows (in thousands):
		Total
	2013 - remaining 3 months	$	747
	2014		781
	2015		—
	2016		—
	Thereafter		10,000
	Total	$	11,528

The_Company_and_Basis_of_Prese2

The Company and Basis of Presentation - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]	'	'
Cash, cash equivalents and marketable securities	$36,338,000	$23,618,000	[1]
Working capital	20,300,000	'
Cash and cash equivalents [Member] | Available-for-sale Securities [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, cash equivalents and marketable securities	$32,500,000	'
[1]	The condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Schedule of Inventory (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'
Raw materials	$1,476
Work in process	407
Finished goods	178
Inventory	$2,061

Equity_Transactions_Additional

Equity Transactions - Additional Information (Detail) (USD $)	1 Months Ended		1 Months Ended	2 Months Ended	6 Months Ended	9 Months Ended
	Jun. 30, 2012	Jun. 12, 2012	31-May-13	Sep. 30, 2012	Jul. 30, 2013	Sep. 30, 2013	Jul. 23, 2012	Jul. 20, 2012	Jun. 12, 2012	Jun. 12, 2012
			Equity line of credit [Member]	Equity line of credit [Member]	Equity line of credit [Member]	Equity line of credit [Member]	Equity line of credit [Member]	Equity line of credit [Member]	Before Reverse Stock Split [Member]	After Reverse Stock Split [Member]
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'
Reduction in common stock outstanding, reverse stock split	'	'	'	'	'	'	'	'	119,600,000	12,000,000
Common stock, par value	'	$0.00	'	'	'	'	'	'	'	'
Reverse Stock Split Ratio, Description	'1-for-10	'	'	'	'	'	'	'	'	'
Reclassified from common stock to additional paid-in capital	$11,000	'	'	'	'	'	'	'	'	'
Authorized sale of common stock under the equity line of credit	'	'	'	'	'	'	'	20,000,000	'	'
Common stock, shares issued	'	'	1,437,481	3,489,860	'	'	80,429	'	'	'
Equity line of credit utilized	'	'	'	13,600,000	'	'	'	'	'	'
Period of terms of a Common Stock Agreement	'	'	'	'	'24 months	'	'	'	'	'
Common stock average price per share	'	'	$4.48	$3.88	'	'	'	'	'	'
Common stock net proceeds	'	'	6,300,000	13,400,000	'	'	'	'	'	'
Available for under the common stock facilities	'	'	$6,400,000	'	'	'	'	'	'	'
Discount of issued shares	'	'	'	'	'	5.00%	'	'	'	'

Fair_Value_Accounting_Financia

Fair Value Accounting - Financial Assets by Major Security Type and Liability Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	($22,523)	'
Total assets	31,173	17,307
Liabilities	'	'
Contingent consideration liability	43,300	9,600
Total liabilities	43,300	9,600
Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	19,869	17,307
Corporate debt securities [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	11,304	'
Level 1 [Member]	'	'
Assets	'	'
Total assets	19,869	17,307
Liabilities	'	'
Contingent consideration liability	'	'
Total liabilities	'	'
Level 1 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	19,869	17,307
Level 2 [Member]	'	'
Assets	'	'
Total assets	11,304	'
Liabilities	'	'
Contingent consideration liability	'	'
Total liabilities	'	'
Level 2 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	'
Level 2 [Member] | Corporate debt securities [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	11,304	'
Level 3 [Member]	'	'
Assets	'	'
Total assets	'	'
Liabilities	'	'
Contingent consideration liability	43,300	9,600
Total liabilities	43,300	9,600
Level 3 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	'
Level 3 [Member] | Corporate debt securities [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	'

Fair_Value_Accounting_Schedule

Fair Value Accounting - Schedule of Cash Equivalents and Marketable Securities (Detail) (USD $)	9 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013
		Money market funds [Member]	Money market funds [Member]	Corporate debt securities [Member]	Total [Member]
Cash Cash Equivalents And Investments [Line Items]	'	'	'	'	'
Amortized Cost	$8,648	$19,869	'	$11,302	$31,171
Fair Value	8,650	19,869	'	11,304	31,173
Unrealized Gain/( Loss)	2	'	'	2	2
Less amounts classified as cash equivalents, Amortized Cost	-22,523	'	'	'	'
Less amounts classified as cash equivalents, Fair Value	-22,523	19,869	17,307	11,304	'
Less amounts classified as cash equivalents, Unrealized Gain/(Loss)	'	'	'	'	'

Fair_Value_Accounting_Addition

Fair Value Accounting - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Sales of marketable securities	$0	$0	$0	$0	'
Marketable securities maximum maturity period	'	'	'1 year	'	'
Increased in net loss resulted from change in discount rate	'	'	3,600,000	'	'
Increased in net loss per share resulted from change in discount rate	'	'	$0.22	'	'
Increase (decrease) on change in fair value of contingent consideration liability	1,613,000	200,000	44,013,000	-1,000,000	'
Increase (decrease) to the net loss, per share	$0.09	$0.02	$2.67	$0.09	'
Estimated fair value of financing obligations	6,127,000	'	6,127,000	'	6,254,000
Book value of financing obligations	$1,524,000	'	$1,524,000	'	$6,461,000	[1]
Maximum [Member]	'	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Cash flow discount rate	'	'	18.00%	'	'
Minimum [Member]	'	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Cash flow discount rate	'	'	16.50%	'	'
[1]	The condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date.

Fair_Value_Accounting_Fair_Val

Fair Value Accounting - Fair Value Measurement of Contingent Consideration Liability (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Fair Value Disclosures [Abstract]	'	'	'	'
Beginning balance	$42,000	$10,300	$9,600	$16,500
Payments made	-313	'	-10,313	-5,000
Adjustments to fair value measurement	1,613	200	44,013	-1,000
Ending balance	$43,300	$10,500	$43,300	$10,500

ShareBased_Compensation_Plans_1

Share-Based Compensation Plans - Additional Information (Detail) (USD $)

9 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

Sep. 30, 2013

Jan. 31, 2013

Jan. 31, 2012

Dec. 31, 2005

Sep. 30, 2013

30-May-13

Dec. 31, 2005

Jan. 31, 2013

Jan. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2005

Sep. 30, 2013

Sep. 30, 2013

Jan. 31, 2013

Jan. 31, 2012

Dec. 31, 2005

Sep. 30, 2013

30-May-13

2005 Equity Incentive Plan [Member]

2005 Equity Incentive Plan [Member]

2005 Equity Incentive Plan [Member]

2005 Equity Incentive Plan [Member]

2005 Equity Incentive Plan [Member]

2005 Equity Incentive Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

Maximum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized for issuance there under share of common stock

'

'

'

108,879

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

Vesting period for stock options and restricted stock units

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

Maximum contractual term for issuing new grants stock options and restricted stock units

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

Increase in annual reserve by percentage of shares of common stock

'

'

'

2.00%

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

Common stock additional shares reserve for issuance/Maximum potential increase in annual reserve of shares

'

100,000

100,000

'

'

'

100,000

75,000

72,136

'

'

'

'

'

75,000

'

19,812

20,000

'

'

'

Authorized additional shares pending approval

'

'

'

'

'

2,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

Intrinsic value of options exercised

$11,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for issuance

'

'

'

'

994,067

'

'

'

'

'

'

'

'

'

'

110,283

'

'

'

166,249

'

Employee stock purchase plan current offering period

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

Purchase price as a percentage of the Company's common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

Shares issued under ESPP

'

'

'

'

'

'

'

'

'

0

0

18,843

2,978

'

'

'

'

'

'

'

'

Weighted average price

'

'

'

'

'

'

'

'

'

$3.65

$5.30

$3.65

$5.30

'

'

'

'

'

'

'

'

ShareBased_Compensation_Plans_2

Share-Based Compensation Plans - Summary of Option Activity under Company's Share-Based Compensation Plans (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Outstanding at January 1, 2013, Number of Shares	1,038,245
Options granted, Number of Shares	1,308,430
Options exercised, Number of Shares	-8,525
Options canceled, Number of Shares	-264,425
Outstanding at September 30, 2013, Number of Shares	2,073,725
Outstanding at January 1, 2013, Weighted Average Exercise Price	$12.24
Options granted, Weighted Average Exercise Price	$4.46
Options exercised, Weighted Average Exercise Price	$3.48
Options canceled, Weighted Average Exercise Price	$10.52
Outstanding at September 30, 2013, Weighted Average Exercise Price	$7.59

ShareBased_Compensation_Plans_3

Share-Based Compensation Plans - Summary of Restricted Stock Unit Activity under Company's Share-Based Compensation Plans (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Outstanding at January 1, 2013, Number of Shares	'
Granted, Number of Shares	590,495
Released, Number of Shares	-17,795
Forfeited, Number of Shares	-45,750
Outstanding at September 30, 2013, Number of Shares	526,950
Outstanding at January 1, 2013, Weighted Average Grant-Date Fair Value	'
Granted, Weighted Average Grant-Date Fair Value	$4.67
Released, Weighted Average Grant-Date Fair Value	$4.20
Forfeited, Weighted Average Grant-Date Fair Value	$4.68
Outstanding at September 30, 2013, Weighted Average Grant-Date Fair Value	$4.68

ShareBased_Compensation_Weight

Share-Based Compensation - Weighted Average Fair Value of Employee Stock Options, Restricted Stock Units and Stock Purchase Rights Granted (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock Options	$3.43	$2.57	$3.46	$2.58
Restricted Stock Units	'	'	$4.67	'
Restricted Stock Units [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted Stock Units	'	'	$4.67	$4.90
Stock Purchase Rights [Member] | Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted Stock Units	$1.41	$3.31	$1.53	$4.23

ShareBased_Compensation_Estima

Share-Based Compensation - Estimated Grant Date Fair Values of Stock Options with Weighted Average Assumptions (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock Option Plans [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected term	'5 years	'5 years	'5 years	'5 years
Expected volatility	98.00%	98.00%	100.00%	98.00%
Risk-free interest rate	1.47%	0.62%	0.83%	0.63%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected term	'6 months	'6 months	'6 months	'7 months 6 days
Expected volatility	63.00%	135.00%	70.00%	96.00%
Risk-free interest rate	0.12%	0.15%	0.13%	0.13%
Dividend yield	0.00%	0.00%	0.00%	0.00%

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total unrecognized compensation expense related to unvested stock option awards	4,470,000
Unvested Stock Option Awards [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expenses expected to be recognized over a weighted average period	'2 years 1 month 6 days
Restricted Stock Units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total unrecognized compensation expense	1,974,000
Expenses expected to be recognized over a weighted average period	'3 years 6 months
Employee Stock Purchase Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total unrecognized compensation expense	12,000
Expenses expected to be recognized over a weighted average period	'1 month 6 days

Net_Loss_per_Share_AntiDilutiv

Net Loss per Share - Anti-Dilutive Securities Excluded from Net Loss per Share (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	2,031,155	834,463	1,541,034	790,892
Restricted stock units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	526,950	150,274	263,475	150,609
Warrants to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	6,462,066	6,462,066	6,462,066	5,362,082
Convertible debt [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	1,115,250	'	557,625	'

Financing_Obligations_Addition

Financing Obligations - Additional Information (Detail) (USD $)	9 Months Ended	1 Months Ended			3 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended		1 Months Ended
	Sep. 30, 2013	Feb. 28, 2011	Jun. 30, 2010	31-May-13	Sep. 30, 2013	31-May-10	Sep. 30, 2013	31-May-10	Jun. 30, 2010	Feb. 28, 2011
		Autoliv ASP, Inc. [Member]	Autoliv ASP, Inc. [Member]	Teva Pharmaceuticals USA, Inc. [Member]	Teva Pharmaceuticals USA, Inc. [Member]	Hercules Technology Growth Capital [Member]	Hercules Technology Growth Capital [Member]	Hercules Technology Growth Capital [Member]	Original Note [Member]	New Note [Member]
								Prime Rate [Member]	Autoliv ASP, Inc. [Member]	Autoliv ASP, Inc. [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Borrowing under loan agreement	'	'	'	'	'	$15,000,000	'	'	'	'
Rate of interest for amount remaining	'	'	'	'	'	10.75%	'	'	'	'
Prime rate plus percentage spread	'	'	'	'	'	'	'	6.50%	'	'
Loan interest prime rate, maximum	'	'	'	'	'	14.00%	'	'	'	'
Installment period of New Note	'	'	'	'	'	'33 months	'	'	'	'48 months
Loan payment date	'	'	'	'	'	'	31-Oct-13	'	'	'
Contractual term of the warrant	'	'	'	'	'	'5 years	'	'	'	'
Additional warrant issued to purchase shares	'	'	'	'	'	37,639	'	'	'	'
Additional exercise price of warrants to purchase common stock	'	'	'	'	'	26.9	'	'	'	'
Warrant expiration date	'	'	'	'	'	'2015-05	'	'	'	'
Estimated the fair value of warrant	'	'	'	'	'	921,000	'	'	'	'
Contractual term of the warrant	'	'	'	'	'	'5 years	'	'	'	'
Risk-free interest rate	'	'	'	'	'	2.31%	'	'	'	'
Expected volatility rate	'	'	'	'	'	84.00%	'	'	'	'
Expected dividend yield	'	'	'	'	'	0.00%	'	'	'	'
Amount of cash paid to Autoliv ASP, Inc.	'	'	4,000,000	'	'	'	'	'	'	'
Value of unsecured promissory note issued	'	'	'	'	'	'	'	'	4,000,000	2,800,000
Value of cancelled note	'	4,000,000	'	'	'	'	'	'	'	'
Debt instrument interest rate	'	'	'	4.00%	'	'	'	'	'	8.00%
Periodic payment of New Note	'	'	'	'	'	'	'	'	'	68,000
Agreement termination date	'	'2016-10	'	'	'	'	'	'	'	'2016-10
Aggregate term loan advances	'	'	'	25,000,000	'	'	'	'	'	'
Debt instrument conversion price per share	'	'	'	$4.48	'	'	'	'	'	'
Number of years from effective date to receive note advances	'	'	'	'2 years	'	'	'	'	'	'
Proceeds from financing obligations	10,000,000	'	'	'	10,000,000	'	'	'	'	'
Unamortized discount from financing obligation	'	'	'	'	2,455,000	'	'	'	'	'
Unamortized borrowing cost from financing obligation	'	'	'	'	$901,000	'	'	'	'	'
Effective interest rate of notes	'	'	'	'	13.90%	'	'	'	'	'

Financing_Obligations_Future_S

Financing Obligations - Future Scheduled Principal Payments under Term Loan Agreements (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'
2013 - remaining 3 months	$747
2014	781
2015	'
2016	'
Thereafter	10,000
Total	$11,528

Facility_Leases_Additional_Inf

Facility Leases - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 30, 2012	Sep. 30, 2013	Sep. 30, 2013
			Lease		2023 Building [Member]	2023 Building [Member]	2091 Building [Member]
					sqft
					Buildings
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Expiry of lease of 2091 Building	'	'	'	'	'	'	31-Mar-18
Operating leases maturity period	'	'	'	'	'	'5 years	'5 years
Number of lease renewal options	'	'	2	'	'	'	'
Termination of 2023 lease Building, square feet	'	'	'	'	41,290	'	'
No of subleases cancelled in 2023 Building	'	'	'	'	2	'	'
General and administrative expenses	$3,097,000	$2,338,000	$12,016,000	$6,487,000	$1,421,000	'	'

License_Agreements_Additional_

License Agreements - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Aug. 31, 2010

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2012

Oct. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

31-May-13

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Cypress Bioscience, Inc. [Member]

Cypress Bioscience, Inc. [Member]

Cypress Bioscience, Inc. [Member]

Cypress Bioscience, Inc. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

License Agreements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-refundable upfront payment received

'

'

'

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential payment for continuing technology development

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Carried interest percentage before technology transfer

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Carried interest percentage after technology transfer

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development fund received

'

'

'

'

3,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue under agreement

2,166,000

729,000

46,530,000

3,341,000

'

0

0

1,259,000

'

'

729,000

729,000

2,187,000

2,082,000

'

'

'

'

Deferred revenue

'

'

'

'

'

'

0

'

'

'

5,829,000

'

5,829,000

'

'

'

'

'

Company received upfront cash payment

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

40,000,000

'

'

'

Cash paid to the former stockholders of Symphony Allegro

'

'

'

'

'

'

'

'

'

'

312,500

'

5,000,000

'

'

'

10,000,000

'

Eligible receipt of additional milestone payments

'

'

'

'

'

'

'

'

'

51,000,000

'

'

48,000,000

'

'

'

195,000,000

'

License agreement contractual terms

'

'

'

'

'

'

'

'

'

'

'

'

'Until the later of the last to expire patent covering ADASUVE in such country or 12 years after first commercial sale

'

'

'

'

'

License agreement term period

'

'

'

'

'

'

'

'

'

'

'

'

'12 years

'

'

'

'

'

Aggregate purchase price

'

'

'

'

'

'

'

'

241,936

'

'

'

'

'

'

'

'

'

Purchase of common stock, value

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

Common stock price, per share

'

'

'

'

'

'

'

'

$12.40

'

'

'

'

'

'

'

'

'

Premium on stock sold

'

'

'

'

'

'

'

'

1,452,000

'

'

'

'

'

'

'

'

'

Estimated performance period of agreement

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

Recognized revenue on the first milestone

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

Aggregate term loan advances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

Number of years from effective date to receive note advances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

Expected volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

Estimated debt yield

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

'

Fair value of right-to-borrow note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,800,000

'

'

'

Interest expense amortization period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

Proceeds from financing obligations

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

Unamortized borrowing cost from financing obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

901,000

901,000

'

Interest expense under right-to-borrow note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

348,000

555,000

'

Eligible receipt of additional payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$195,000,000

Autoliv_Manufacturing_and_Supp1

Autoliv Manufacturing and Supply Agreement - Additional Information (Detail) (Autoliv ASP, Inc. [Member], USD $)	1 Months Ended
	Feb. 28, 2011	Jun. 30, 2010	Nov. 30, 2007
			Package
Debt Instrument [Line Items]	'	'	'
Production of Chemical Heat Packages	'	'	10,000,000
Amount of cash paid to Autoliv ASP, Inc.	'	$4,000,000	'
Value of cancelled note	4,000,000	'	'
Cost to complete and acquire production line of second cell	1,200,000	'	'
Expenses related to the equipment and tooling	12,000,000	'	'
Number of days payment is due upon certain criteria	'60 days	'	'
Agreement termination date	'2016-10	'	'
New Note [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Installment period of New Note	'48 months	'	'
Periodic payment of New Note	68,000	'	'
Value of unsecured promissory note issued	2,800,000	'	'
Agreement termination date	'2016-10	'	'
Original Note [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Value of unsecured promissory note issued	'	$4,000,000	'